Skip to search formSkip to main contentSkip to account menu

tinzaparin

Known as: B01AB10, tinzaparin [Chemical/Ingredient] 
A drug that is used with another drug, warfarin, to treat blood clots that form deep in the veins and to prevent new blood clots from forming. It is… 
National Institutes of Health

Related topics

Related topics

11 relations
Drug AllergyHemorrhagic DisordersPulmonary EmbolismThrombocytopenia

Broader (2)

Fibrinolytic AgentsHeparin, Low-Molecular-Weight

Narrower (2)

InnohepTinzaparin sodium

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
LBA-2 A randomized trial of long-term tinzaparin, a Low Molecular Weight Heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients-the CATCH study
Background Patients with cancer and VTE have a substantial risk of recurrent VTE. LMWH reduces the risk of symptomatic… 
Review
2013
Review
2013
Characterization of currently marketed heparin products: key tests for LMWH quality assurance.
2012
2012
The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.
2011
2011
Effects of Antithrombotic Drugs Fondaparinux and Tinzaparin on In Vitro Proliferation and Osteogenic and Chondrogenic Differentiation of Bone-Derived Mesenchymal Stem Cells
An unexpected side effect of some classes of anticoagulants has been osteoporosis which may be, at least in part, related to… 
2010
2010
Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study
The objective of the present study was to evaluate the efficacy, safety and healthcare resource utilization of long-term… 
Highly Cited
2006
Highly Cited
2006
Outpatient tinzaparin therapy in pulmonary embolism quantified with ventilation/perfusion scintigraphy.
BACKGROUND Out-of-hospital treatment of patients with deep-vein thrombosis (DVT) is routine in many countries regardless of… 
Review
2006
Review
2006
Use of Low‐Molecular‐Weight Heparin to Bridge Therapy in Obese Patients and in Patients with Renal Dysfunction
Objective. To recommend strategies to bridge therapy with low‐molecular‐weight heparin (LMWH) in obese patients and in patients… 
2005
2005
Pharmacokinetics of UH and LMWH are similar with respect to antithrombin activity.
Highly Cited
2005
Highly Cited
2005
Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides
Summary Eczematous lesions, resulting from type IV sensitizations are well-known and relatively frequent cutaneous adverse… 
2002
2002
Inhibitory effect of C-reactive protein on the release of tissue factor pathway inhibitor from human endothelial cells: reversal by low molecular weight heparin.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)